Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Postive Results from Meningococcal Disease Trial

By Drug Discovery Trends Editor | June 10, 2011

New data from a pivotal study in more than 1,800 infants show that Novartis candidate vaccine Bexsero (Multicomponent Meningococcal Serogroup B Vaccine) induces a robust immune response to meningococcal serogroup B when given alone or when co-administered with other routine vaccines. These results also show that Bexsero can fit into various vaccination schedules in the first year of life, when the likelihood of contracting this often-deadly disease is greatest. The study also demonstrated that Bexsero has an acceptable tolerability profile.
 
Data from another pivotal study in more than 1,500 toddlers shows that Bexsero provides protective immune response when used as a booster in toddlers already primed, or after two doses in those not previously vaccinated with Bexsero. A third study presented showed that Bexsero induces a strong immune response in adolescents against meningococcal serogroup B (MenB). The data were presented at The European Society for Paediatric Infectious Diseases (ESPID) in The Hague, The Netherlands.
 
These data are included in the comprehensive clinical program with Bexsero in more than 8,000 infants, toddlers, adolescents and adults which served as the basis of the registration file submitted to the European Medicines Agency (EMA) in December 2010.
 
“MenB disease poses a significant burden to people around the world, particularly infants, the population at greatest risk for the disease,” said Andrin Oswald, Head of Novartis Vaccines and Diagnostics Division. “The data show that Bexsero, our innovative multicomponent MenB vaccine, holds great promise in providing a solution to a major public health concern that can have a devastating impact on vulnerable populations.”
 
MenB is the most common cause of bacterial meningitis for which there is no effective routine vaccine, and it is responsible for up to 90% of meningococcal disease cases in Europe, and over 80% of meningococcal cases in infants in Canada. Survivors may suffer permanent brain damage, learning disabilities, hearing loss, and limb loss.
 
“The serious and long-term effects of MenB are often devastating to its victim, family members and the community at large,” said Jamie Findlow PhD, Deputy Head of the Health Protection Agency, Vaccine Evaluation Unit, Manchester, UK. “The rapid disease progression3 and flu-like symptoms of MenB can be difficult to recognize, particularly in infants, making prevention through vaccination the most effective way to control this disease.”
 
Bexsero has the potential to provide protection against a broad range of MenB strains. If licensed, Bexsero could fill a public health need across multiple regions that is not met by currently available vaccines. Recent data have shown that Bexsero could be expected to provide protection against approximately 80% of more than 1,000 disease-causing MenB strains isolated in Europe in 2007-2008.

Date: June 9, 2011
Source: Novartis Vaccines and Diagnostics 


Filed Under: Drug Discovery

 

Related Articles Read More >

Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority
Portrait photo of Pfizer EVP and Medtronic board member Lidia Fonseca
Medtronic appoints Pfizer EVP as independent board director

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50